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Abstract Sodium retention and edema are common fea-
tures of nephrotic syndrome that are classically attributed to
hypovolemia and activation of the renin–angiotensin–
aldosterone system. However, numbers of clinical and
experimental findings argue against this underfill theory.
In this review we analyze data from the literature in both
nephrotic patients and experimental models of nephrotic
syndrome that converge to demonstrate that sodium
retention is not related to the renin–angiotensin–aldosterone
status and that fluid leakage from capillary to the
interstitium does not result from an imbalance of Starling
forces, but from changes of the intrinsic properties of the
capillary endothelial filtration barrier. We also discuss how
most recent findings on the cellular and molecular
mechanisms of sodium retention has allowed the develop-
ment of an efficient treatment of edema in nephrotic
patients.
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Introduction
Interstitial edema is a common clinical feature of nephrotic
syndrome (NS). It is often massive (up to 30% of body
weight) and constitutes a functional constraint, owing to
locomotive restriction and eyelid shutting. Expansion of the
interstitial compartment volume results from the combina-
tion of abnormal renal sodium retention and alterations of
fluid transfer across capillary walls.
Renal retention of sodium in nephrotic syndrome
Site of sodium retention Most of our current knowledge on
the site and mechanism of renal sodium retention in NS
comes from experimental models of the disease, in
particular the puromycin aminonucleoside (PAN) rat model.
Following a single injection of PAN, rats develop massive
proteinuria within 4–5 days and sodium retention within 2–
3 days. Sodium excretion resumes after 9–10 days, while
proteinuria lasts for 2–3 weeks [1, 2]. Unilateral NS can be
induced by the injection of PAN into one of the renal
arteries [3]. Early in vivo micropuncture studies in rats with
unilateral PAN nephrosis demonstrated that sodium reten-
tion in the nephrotic kidney originates beyond the last
nephron segment accessible to micropuncture, i.e., between
the late distal convoluted tubule and the tip of the collecting
duct [3]. This part of the nephron encompasses the
connecting tubule and the cortical and outer medullary
collecting ducts, which reabsorb sodium and are the major
sites of the adjustment of sodium balance under the
homeostatic control of aldosterone, and the inner medullary
collecting duct, which is able to secrete an overload of
sodium in response to atrial natriuretic peptide [4]. Methods
allowing in vitro analysis of isolated sub-segments of the
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Paris, Francedistal nephron demonstrated a marked stimulation of
sodium reabsorption in the cortical collecting duct (CCD)
of PAN nephrotic rats [1, 5]. This stimulation of sodium
transport likely extends upstream to the connecting duct but
not downstream to the outer medullary collecting duct. In
addition, in NS, the inner medullary collecting duct
becomes insensitive to the natriuretic action of atrial
natriuretic peptide [6–8], thereby preventing any compen-
sation of sodium retention in upstream nephron segments.
Cellular mechanism of sodium retention in the collecting
duct In vitro microperfusion of isolated CCDs confirmed
that the rate of sodium reabsorption and the trans-epithelial
voltage are negligible in CCDs from control rats, whereas
both are high in CCDs from PAN nephrotic rats [5]. CCDs
are made of principal and intercalated cells, which account
for sodium and water reabsorption and potassium secretion
for principal cells, and proton, bicarbonate and likely
chloride transport for intercalated cells [4]. In principal
cells, sodium reabsorption proceeds along a two-step
mechanism (Fig. 1): Na,K-ATPase, exclusively present in
the basolateral membrane, energizes the active extrusion of
sodium at the expense of ATP hydrolysis. The electro-
chemical gradient for sodium generated by this primary
process drives passive entry of sodium through the apical
membrane, which contains selective sodium channels
(epithelial sodium channels, ENaCs). Both Na,K-ATPase
and ENaCs are targets for multiple, and often coordinated,
regulations in CCDs [4].
Increased sodium reabsorption along the CCDs of PAN
nephrotic rats, as well as sodium retention and edema
formation, are associated with stimulation of both baso-
lateral Na,K-ATPase [1, 9, 10] and apical ENaC [11–13]
(Fig. 1), but the latter is dispensable (see below).
Stimulation of Na,KATPase is fully accounted for by
transcriptional induction of its α and β subunits and
targeting of newly synthesized pumps to the basolateral
membrane of principal cells [14]. In contrast, stimulation of
ENaC mainly results from the targeting of a pre-existing
pool of latent intracellular channels to the apical membrane
of principal cells and slightly from transcriptional induction
of the α and β subunits [11–13]. The patch-clamp
technique shows that the intrinsic properties of ENaC (open
probability and unitary conductance) are not altered in the
CCD of nephrotic animals [13].
Fig. 1 Cellular mechanism of sodium reabsorption in principal cells
of collecting ducts from normal rats and nephrotic rats. Sodium
reabsorption in principal cells proceeds along a two-step mechanism
that includes active extrusion of intracellular sodium ions by the
basolateral Na,K-ATPase and passive apical entry of sodium via the
amiloride-sensitive epithelial sodium channel (ENaC). In CCDs from
normal rats (top panels), most ENaCs are sequestered in the
intracellular compartment of principal cells (left panel), and basolateral
expression of Na,K-ATPase in collecting ducts (asterisk) principal
cells is very weak, in comparison with that in thick ascending limbs
(T) and even proximal tubules (P)( right panel). Accordingly, the rate
of sodium reabsorption is very low. In CCDs from PAN nephrotic rats
(bottom panels), ENaC is expressed at the apical border of principal
cells (left panel), and expression of basolateral Na,K-ATPase is
drastically increased in collecting ducts (asterisk). Polarized increases
in expression of ENaC and Na,K-ATPase in principal cells account for
increased sodium reabsorption in CCDs. In both normal and nephrotic
rats expression of Na,K-ATPase is undetectable in the glomerulus (G);
in CCDs, unlabeled cells for both ENaC and Na,K-ATPase are
intercalated cells (redrawn from [13, 14])
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tors are not involved in sodium retention in nephrotic
syndrome Historically, it is acknowledged that sodium
retention and edema formation result from hypovolemia-
induced stimulation of the renin–angiotensin–aldosterone
system. Hypovolemia is supposed to proceed as follows:
proteinuria induces hypoalbuminemia and reduces plasma
oncotic pressure, which generates an imbalance of Star-
ling’s forces across capillary walls, leading to interstitial
leakage of fluid and decreased efficient volume [15].
Although this mechanism is consistent with the renal site
of sodium retention, with the activation of ENaC and the
induction of Na,K-ATPase in the collecting duct, and with the
hyperaldosteronemia observed in PAN nephrotic rats [13], a
large body of clinical evidence argues against this theory.
– Analbuminemic patients display no sodium retention
and no, or only modest, edema, despite low plasma
oncotic pressure [16].
– In children with steroid-sensitive minimal change
disease, natriuresis resumes at the same time as
proteinuria stops, before normalization of albuminemia
[17].
– Blood volume is not correlated with plasma oncotic
pressure in nephrotic patients [18].
– Among children with relapse idiopathic nephrotic
syndrome, (a) 21% display hypertension but only 4%
exhibit collapse [19], and (b) only 1% display low
blood volume, whereas 17% present hypervolemia
[20].
– Intravenous injection of albumin induces volume
expansion but promotes only mild natriuresis (reviewed
in [21]).
– Blockade of mineralo-corticoid receptor or inhibition of
angiotensin-converting enzyme has no effect on natri-
uresis in most patients [22, 23].
The lack of a role for hyperaldosteronemia in sodium
retention in NS was directly demonstrated in PAN nephrotic
rats. In this model it is possible to blunt PAN-induced
hyperaldosteronemia through bilateral adrenalectomy and
corticosteroid replacement through implanted mini-pumps
delivering constant physiological level of aldosterone and
glucocorticoids. Administration of PAN to these corticoste-
roid-clamped rats reduces sodium excretion, establishes
sodium balance and promotes ascites formation with similar
time course and intensity as in adrenal-intact rats [11, 13].
These findings also exclude a possible role in sodium
retention ofpromiscuous activationof themineralo-corticoid
receptor (MR) by glucocorticoid brought about by decreased
11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2).
Indeed, use of dexamethasone instead of corticosterone for
glucocorticoid replacement prevents MR activation, even in
the presence of 11β-HSD2 inhibition. The lack of involve-
ment of MR activation in sodium retention in nephrotic
syndrome is consistent with the fact that nephrotic syndrome
does not induce potassium secretion.
None of the known factors that control sodium reabsorption
in the collecting duct accounts for sodium retention in PAN-
nephrotic rats Since aldosterone, the major factor that
controls sodium reabsorption in collecting ducts, is not
involved in sodium retention, several hormones or para-
crine factors that modulate this process have been consid-
ered as putative candidates:
– Vasopressin (AVP), through activation of its V2
receptors coupled to the cAMP pathway, increases
sodium reabsorption in the collecting duct synergisti-
cally with aldosterone [24, 25].
– Angiotensin II (AII) increases sodium reabsorption
directly through activation of AT1 receptors coupled
to phospholipase C, independently of the induction of
aldosterone release [26].
– Insulin-like growth factor I (IGF-1) used in the
treatment of insulin resistance in type 2 diabetes can
induce sodium retention and edema [27], likely through
its stimulatory action on sodium transport along the
collecting duct [28].
– In mouse collecting duct cells, tumor necrosis
factor alpha (TNFα) increases membrane expression
of Na,K-ATPase [29], and administration of etanercept,
a TNFα receptor antagonist, to diabetic rats induces
natriuresis [30].
– More recently, the thiazolidinedione agonists of perox-
isome proliferator-activated receptor γ (PPARγ) were
reported to induce sodium retention [31] through a
stimulatory effect on the collecting duct [32].
– Quite unexpectedly, inhibition of nitric oxide synthase
promotes sodium excretion in cirrhotic rats with ascites
[33].
Except for AII, all maneuvers aimed at blocking these
different pathways had no effect on sodium retention in
nephrotic syndrome (Fig. 2). Only the AT1 blocker
irbesartan was able to improve sodium excretion, although
not up to normal level. However, this effect was limited to
the initial sodium retention observed 2–4 days after PAN
administration and did not alter the main effect observed at
days 5 and 6. This suggests that AII, independently of
aldosterone, may be involved in the early retention of
sodium observed after the peak of sodium excretion at
day 1.
As a matter of fact, sodium retention in PAN nephrosis
unlikely results from the presence of an abnormal blood
concentration of any factor, since only the treated kidney
displays increased sodium reabsorption in unilateral PAN-
nephrotic rats. Rather, alterations in collecting duct function
Pediatr Nephrol (2007) 22:1983–1990 1985may be accounted for either by a direct effect of PAN on
CCD or by the abnormal presence of an unidentified
stimulatory factor in the luminal fluid that reaches the
distal nephron. The presence of this factor may result from
its abnormal filtration secondarily to the alteration of the
glomerular filtration barrier (e.g., a high molecular weight
protein), or from its generation in the proximal tubule
secondarily to alteration of protein/peptide handling.
Na,K-ATPase is the primary target of sodium retention in
PAN nephrosis Analysis of corticosteroid-clamped rats not
only demonstrated that hyperaldosteronemia is not involved
in the etiology of edemas in NS, but it also provided
insights into the primary molecular target of sodium
retention in the CCD. Indeed, in CCDs from corticoste-
roid-clamped PAN rats, Na,K-ATPase is induced as in
adrenal-intact nephrotic rats [13]. In contrast, targeting of
ENaC to the apical membrane is fully blunted [11, 13], and
the residual channels expressed at the apical membrane are
drastically inhibited, as their open probability is reduced
>10-fold [13].
Thus, induction of Na,K-ATPase is primarily responsible
for sodium retention in PAN nephrotic syndrome. This
conclusion likely applies to all experimental models of
nephrotic syndrome and, possibly, to the disease in humans,
since there is a significant reverse correlation between Na,
K-ATPase activity in collecting duct and urinary sodium
excretion during the phase of sodium retention in rats with
nephrotic syndrome induced by PAN, Adriamycin or
mercury chloride [1].
Edema formation in nephrotic syndrome
Most sodium-retaining states are associated with high blood
pressure but not with development of edema or ascites.
Edema formation in NS results from the asymmetry of
extracellular volume expansion brought about by sodium
retention: the vascular volume is not, or only slightly,
modified, whereas water and solutes accumulate in the
interstitium. Distribution of fluid between vascular and
interstitium compartments is governed by fluid exchanges
across the capillary wall and by lymphatic draining.
Capillary filtration capacity is increased almost twofold in
nephrotic patients [34]. This fluid leakage is governed by
several parameters according to Starling’s law:
Jv ¼ Lp   S   Pc   Pi ðÞ   s   Πc   Πi ðÞ ½ 
where Jv is the trans-capillary flux of fluid, Lp the hydraulic
conductivity of capillaries, S the exchange surface, Pc and
Pi the hydrostatic pressure of the capillary and interstitium,
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Fig. 2 Profile of sodium excretion in PAN nephrotic rats. Daily
urinary sodium excretion, expressed as a function of urinary creatinine
excretion, following administration of puromycin aminonucleoside
(150 mg/kg body wt, intravenously) in normal rats (dotted lines)o r
genetically modified or pharmacologically treated rats (solid lines).
Arrows or grey boxes show the time of treatment. Brattleboro rats
genetically lack vasopressin secretion. JB1, an inhibitor of IGF-1
receptors, was continuously administered via subcutaneous mini-
pumps at a dose of 12 μg/100 g body wt per day, starting on day 3.
The antagonist of AT1 receptor, irbesartan, was administered per os at
a dose of 2 mg/100g body wt per day. Etanercept, a chimeric antibody
directed against TNF receptor, was administered twice (days −1 and 2)
at a dose of 0.2 mg/100g body wt. The inhibitor of nitric oxide
synthase, L-NAME, was administered twice daily by gavage (0.5 mg/
100 g body wt per 12 h) throughout the study. The antagonist of
PPARγ, SR202, was given per os at a dose of 20 mg/100 g body wt. All
controls were treated in parallel with the vehicle. Values are means ± SE
from 4–5r a t s
1986 Pediatr Nephrol (2007) 22:1983–1990respectively, σ the reflection coefficient of proteins across
the capillary wall, and Πc and Πi the oncotic pressure in the
capillaries and interstitium, respectively.
Unexpectedly, data from the literature indicate that the
increase in Jv in NS is not accounted for by change in the
oncotic pressure gradients, as intuitively thought, but by
changes in the intrinsic properties of the capillary walls that
govern their hydraulic conductance and reflexion coeffi-
cient for proteins. This means that the capillary wall is a
direct target in NS, to the same right as the glomerular
filtration barrier.
The trans-capillary gradient of oncotic pressure (Πc–Πi)i s
unchanged in NS The lack of edema and ascites in
analbuminemic rats and patients [16, 35] has questioned
the importance of low plasma oncotic pressure in the
genesis of edema in NS. As a matter of fact, the trans-
capillary gradient of oncotic pressure is unchanged in
analbuminemic rats, owing to a parallel decrease in plasma
and interstitium oncotic pressure [35]. Experiments in dogs,
in which plasma oncotic pressure was progressively
decreased by 50% through plasmapheresis, showed that
the interstitium oncotic pressure decreased in parallel and
that the trans-capillary gradient remained unaffected.
Extracellular volume increased transiently during the phase
of variation of plasma oncotic pressure, in response to
hyperaldosteronemia and renal sodium retention, but
returned to normal level during the period of stabilized
low plasma oncotic pressure [36].
Essentially similar observations were made in humans.
During NS, it was also observed that the oncotic pressure of
the interstitium decreases in parallel with that of the
vascular compartment, so that the trans-capillary gradient
is only slightly reduced [37]. In addition, diuretic treat-
ments [37] or extracorporeal ultrafiltration [38] allow the
withdrawal of significant amounts of edema without
significant change in the trans-capillary gradient of oncotic
pressure.
Thus, decrease in plasma oncotic pressure in animal
models as well as in nephrotic patients does not alter
significantly the trans-capillary gradient of oncotic pressure
and is neither a determinant parameter in the genesis of
edema nor a resistance factor to edema withdrawal.
The trans-capillary gradient of hydrostatic pressure (Pc–Pi)
is unchanged in NS Capillary pressure is unchanged in
nephrotic patients [34]. Because soft tissues display an
almost infinite compliance, their interstitium pressure
increases by only 2 mmHg with their fluid filling [39]. In
nephrotic patients interstitial pressure in edematous and
non-edematous sectors differs by <4 mmHg [40]. Thus, it
can be admitted that the trans-capillary gradient of
hydrostatic pressure is not significantly altered in soft
edematous tissues during NS.
The capillary hydraulic conductivity Lp is increased in
NS The threshold of venous pressure triggering fluid
transfer across capillaries is significantly reduced in NS
[34], suggesting that endothelial Lp is decreased. The main
determinants of the hydraulic conductivity of capillaries are
the occlusive junctions (constituted by occludin, claudins
and proteins ZO) and adhesive junctions (made of
cadherins, catenins and actinin) between endothelial cells.
These proteins are direct targets for intracellular signaling
cascades, in particular protein kinase C (PKC), which
phosphorylates occludin [41] and alters the endothelial
permeability [42]. In NS this pathway may be activated
through two mechanisms. Firstly, hypoalbuminemia
increases Lp via an increase in intracellular calcium [43].
Secondly, high plasma levels of TNFα observed in patients
with minimal change disease [44] activate PKC and
increase Lp [45].
The reflexion coefficient of proteins (σ) is increased in
NS Increased coefficient of reflexion of macromolecules in
NS is evidenced by the higher rate of leakage of
technetium-labeled albumin towards the interstitium in
nephrotic patients than in controls [46]. Because this
change in reflexion coefficient is observed in patients with
NS of different origin, it is likely not accounted for by the
circulating permeability factor of lymphocyte origin re-
sponsible for glomerular hyperfiltration in minimal change
disease. Increased σ was also reported in blood–peritoneal
barrier permeability in PAN-nephrotic rats [47].
Therapeutic implications
Nephrotic edema results from the combination of renal
sodium retention and increased capillary permeability.
Although treatment of either of these two alterations would
prevent edema, treatment of capillary permeability alone
would lead to hypertension. Thus, treatments of edema
must primarily target renal sodium retention.
Different therapeutic strategies are needed to prevent
edema formation in children with chronic proteinuria and to
treat massive edema. In the first case it is sufficient to
prevent sodium accumulation, either through limiting
dietary sodium uptake or by natriuretic drugs that target
the collecting duct, e.g., amiloride. In clinical practice the
daily uptake of sodium is usually limited to 0.5 mmol/kg.
In PAN-nephrotic rats administration of amiloride starting
before the onset of sodium retention fully prevents sodium
retention and formation of ascites [5].
Pediatr Nephrol (2007) 22:1983–1990 1987More classically, clinicians are confronted with patients
who already display massive edema. Treatment aims both
at limiting further sodium retention and at promoting the
excretion of the mass of sodium and water sequestered in
edema. While amiloride is well suited to block further
sodium retention, it is inefficient in promoting massive
sodium excretion, because, under normal conditions, sodium
reabsorption along the collecting duct is quantitatively low.
Recourse to more potent diuretics, such as loop diuretics, is
restricted by the functional resistance of nephrotic patients to
the natriuretic effect of furosemide. Several explanations
have been proposed to account for this resistance, but none
has been confirmed:
– The pharmacokinetics of furosemide urinary elimina-
tion is not significantly altered in nephrotic children
[48]
– Binding of furosemide to albumin in the tubular fluid
does not account for furosemide resistance, since,
despite controversial data [49, 50], inhibitors of
furosemide–albumin binding do not improve sodium
excretion significantly.
– The intrinsic sensitivity of the Na/K/2Cl transporter of
the loop of Henle, the molecular target of furosemide,
is not altered in nephrotic rats [5].
Based on our present knowledge of the site and cellular
mechanism of sodium retention in NS, another explana-
tion of furosemide resistance, and a therapeutic strategy to
circumvent it, can be proposed. In non-nephrotic patients,
furosemide decreases sodium reabsorption along the thick
ascending limb of the loop of Henle, which increases
sodium delivery to the distal nephron. Because the sodium
reabsorption capacity of the distal nephron is rather
limited, only a small fraction of the overload of sodium
is reabsorbed, and the major fraction is excreted in the
urine, accounting for the natriuretic effect of loop
diuretics. Note that following long-term treatment with
furosemide, there are adaptations of the distal nephron
which increase its sodium reabsorption capacity and,
thereby, reduce the natriuretic effect of furosemide.
Because nephrotic patients display a huge sodium reab-
sorption capacity along their connecting and cortical
collecting tubules, most of the overload of sodium
brought about by furosemide-induced inhibition of trans-
port in the thick ascending limb is reabsorbed, thereby
blunting the natriuretic effect. Thus, the apparent resis-
tance of nephrotic patients to loop diuretics can be
circumvented by the inhibition of distal sodium reabsorp-
tion with amiloride. As a matter of fact, co-administration
of furosemide and amiloride to nephrotic children
increases urinary sodium excretion, induces a negative
sodium balance and promotes complete edema withdrawal
w i t h i n1w e e k[ 21].
Conclusion
Whatever their etiology, nephrotic syndromes are always
associated with renal retention of sodium. Renal sodium
retention results from enhanced sodium reabsorption along
the connecting and cortical collecting ducts and from
blunted responsiveness of medullary collecting ducts to
the natriuretic response to atrial natriuretic peptide. Induc-
tion of de novo synthesis of Na,K-ATPase is the primary
effector of increased sodium reabsorption. It is not
accounted for by any circulating factor, in particular
aldosterone, known to stimulate sodium reabsorption along
the distal nephron. New research strategies will be required
to identify the unknown regulatory pathway that is
dysregulated in NS.
Sodium retention in NS does not lead to high blood
pressure but leads to an asymmetric expansion of the
interstitium, while the vascular volume remains unchanged
in most patients. This asymmetry of extracellular volume
expansion is accounted for by changes in the intrinsic
properties of the endothelial capillary barriers, i.e., an
increase in its hydraulic conductivity and permeability to
proteins, rather than to an imbalance of Starling’s forces.
Thus, the pathophysiology of nephrotic syndrome relies
on at least three disorders: a major alteration of the
glomerular filtration barrier responsible for proteinuria and
hypoalbuminemia, an induction of distal nephron Na,K-
ATPase responsible for sodium retention, and alterations in
the capillary permeability accounting for the asymmetry of
volume expansion. Although causal relationships between
these three events have not been formally established, it is
assumed that the glomerular defect engenders both the
tubular and the capillary alterations. This conclusion is
based on the facts that: (a) whatever its origin, alteration of
the glomerular filtration barrier always leads to sodium
retention and edema formation, i.e., to the tubular and
capillary defects, and (b) loss of function mutations of
nephrin, which is expressed in the glomerular slit dia-
phragm but in neither the collecting duct nor capillary
endothelial cells, is sufficient to promote proteinuria,
sodium retention and edema [51]. Curiously, in PAN-
induced nephrosis, sodium retention precedes proteinuria,
suggesting that it is not secondary to the glomerular
dysfunction. It should be stressed, however, that micro-
proteinuria may appear sooner and concomitantly with
sodium retention.
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